MLYS
NASDAQ · Biotechnology
Mineralys Therapeutics Inc
$25.78
+0.26 (+1.02%)
Analyst Consensus
Strong Buy
16
Analysts
High
Coverage
Price Target
Analyst Price Target
+261.5% upside
Low Target
$50.31
Average Target
$93.19
High Target
$121.15
Current Price
$25.78
Current
$25.78
$25.78
Target
$93.19
$93.19
$50.31
$93.19 avg
$121.15
Scenario Analysis
Bear Case
$50.31
95.2%
Low target
Base Case
$93.19
+261.5%
Avg target
Bull Case
$121.15
+369.9%
High target
Risk/Reward
3.9x
Highly favorable
Price in Context
52-Week High
$47.65
-45.9% from high
52-Week Low
$12.59
+104.8% from low
50-Day SMA
$33.44
-22.9% vs SMA
200-Day SMA
$27.93
-7.7% vs SMA
RSI (14)
35.0
Neutral
Target vs 52W High
$93.19
+95.6% vs high
Next Earnings Report
Aug 11, 2026 · After Market Close
3d
until earnings
EPS Est: $-0.55
Earnings in 3 days. Analyst targets may shift significantly after the report.
Peer Consensus — Biotechnology
| Stock | Consensus | Analysts | Buy % | Target | Upside |
|---|---|---|---|---|---|
| ABBV | Strong Buy | 39 | 79% | $257.58 | +5.4% |
| AMGN | Hold | 43 | 49% | $190.87 | -52.7% |
| GILD | Strong Buy | 37 | 81% | $362.68 | +179.1% |
| VRTX | Strong Buy | 40 | 83% | $438.34 | -9.5% |
| REGN | Buy | 38 | 71% | $76.80 | -90.0% |
| RVMD | Strong Buy | 29 | 93% | $114.11 | -42.1% |
| NTRA | Strong Buy | 30 | 87% | $142.91 | -46.0% |
| BIIB | Buy | 44 | 64% | $91.45 | -55.7% |